In this edition:
FORWARD: a novel allogeneic stem cell-derived islet cell therapy for type 1 diabetes
BELIEVE: bimagrumab + semaglutide in overweight/obesity
STRIDE sub-analysis: semaglutide benefits across diabetes characteristics
ACHIEVE-1: orforglipron in drug-naïve type 2 diabetes
REDEFINE 2: cagrilintide + semaglutide in type 2 diabetes with overweight/obesity
A GPT-based AI model for diabetes education
ADJUST-T1D: add-on semaglutide in type 1 diabetes
Dementia risks with SGLT2is/GLP-1 RAs in type 2 diabetes
Functional MRI findings in painful diabetic neuropathy
QWINT-4: efsitora vs. insulin glargine U100 in type 2 diabetes treated with basal & prandial insulin
Please login below to download this issue (PDF)